Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | UBE2M | P61081 | 1/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787583 | 0.83 | MAPT (0.40) | HDAC1HDAC6RORCRXRARXRB | |
| SCHEMBL1789822 | 0.78 | HRH3 (0.44) | — | |
| SCHEMBL1788201 | 0.75 | MEN1 (0.46) | — | |
| SCHEMBL1786585 | 0.75 | HPGD (0.46) | — | |
| SCHEMBL1789814 | 0.74 | ERCC1 (0.47) | — | |
| SCHEMBL1789593 | 0.73 | ALDH1A1 (0.43) | — | |
| SCHEMBL1790111 | 0.73 | GRIN2B (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Potassium Ion SCHEMBL1787642 | 0.73 | ALDH1A1 (0.34) | — | |
| SCHEMBL1790557 | 0.73 | ALDH1A1 (0.37) | HDAC1HDAC6 | |
| SCHEMBL12010814 | 0.71 | OPRD1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | HDAC1 237/4885HDAC6 683/4885GRIN2D 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.